Ipsen reacts to NICE’s Cabometyx verdict
Company disappointed by institute’s failure to recommend thyroid cancer therapy for specific patient group
Read More
Tag: Cabometyx
Positive results for Ipsen’s Cabometyx in combination with nivolumab
Benefits were identified with Cabometyx in combination with nivolumab across all efficacy measures
Read More
FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer
Cabometyx found to reduce the risk of disease progression or death versus placebo in this patient population
Read More
Opdivo plus Cabometyx approved in the EU for advanced renal cancer
Opdivo plus Cabometyx doubled progression-free survival compared to those receiving Pfizer’s Sutent in a Phase III trial
Read More
Opdivo/Cabometyx combo hits targets in first-line kidney cancer
The combination significantly increased progression free survival when used as a first-line treatment
Read More
Yescarta rejected among other SMC decisions
Gilead’s CAR-T therapy Yescarta has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland, but Novartis’ Kymriah was given a green light.
Read More
Ipsen’s Cabometyx wins EU nod for liver cancer
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
Read More
Four new therapies to be funded by NHS Scotland
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.
Read More
NICE u-turn recommends Ipsen’s Cabometyx for kidney cancer
NHS funding for Ipsen’s Cabometyx is now being recommended by the National Institute for Health and Care Excellence to treat kidney cancer.
Read More
NICE rules against first-line use of Ipsen’s Cabometyx
The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.
Read More
EU OKs first-line use of Ipsen’s Cabometyx
The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
Read More
Cabometyx trial halted early on success in liver cancer
A late-stage trial assessing Ipsen and Exelixis’ Cabometyx in advanced liver cancer has been halted early after a significant improvement in overall survival was observed.
Read More
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
- Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
